Scope of the journal

Oncology Discovery  includes the complete study on cancer that includes prevention, diagnosis, therapy, palliative care, prognosis aspects and ethical issues surrounding cancer care at cellular and molecular levels along with the study related to the malignances and tumors. View More...
Original ResearchOpen Access

Infrared light enables visualization of the prostate carcinoma after radical prostatectomy

Besarion Partsvania, Tamaz Sulaberidze, Alexandre Khuskivadze, Levan Shoshiashvili, Ketevan Chubinidze
Oncology Discovery 4: 2

ReviewOpen Access

Therapeutic strategies to reverse immunosuppressive breast cancer microenvironment

Deimante Tamkus, Tejaswini Joginpally
Oncology Discovery 4: 1

Case reportOpen Access

Calcaneal osteosarcoma, a challenge for diagnosis: a rare case report and literature review

Barada Prasanna Samal, Chandrakant Nayak, Sarita Pradhan, Tapan Kumar Sahoo, Aswini Kumar Jena, Sasmita Pradhan
Oncology Discovery 3: 2

ReviewOpen Access

Preneoplasia and carcinogenesis of the oral cavity

Naoki Watanabe, Tsunemasa Ohkubo, Masahito Shimizu, Takuji Tanaka
Oncology Discovery 3: 1

ReviewOpen Access

Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment

Joris R Julsing, Godefridus J Peters
Oncology Discovery 2: 3

View All articles ..


Prof. Paul J. Higgins
is currently a Professor and Director of the Center for Cell Biology and Cancer Research at the Albany Medical College in Albany, New York. He was the founding Vice President of the Albany Research Institute (ARI) and currently serves on the ARI Board of Directors. He has received several prestigious awards including the Moyer Award and, most recently, the 2008 Excellence Award in Molecular Medicine. Molecular genetic studies in Dr. Higgins laboratory identified the mammalian SERPINE1 gene and the SERPIN family as key elements in the regulation of cell shape, motility, growth control and tissue invasion.

Prof. G. J. Peters
acting Head for the Laboratory Medical Oncology, VU University Medical Center, Netherlands. The major research interests of Prof. Peters include all aspects of pharmacology of anticancer agents, with emphasis on antifolates, other antimetabolites, platinum analogs, taxanes and more recently anti-signalling agents and third generation targeted-agents. The focus is on the improvement of treatment of lung, colon and pancreatic cancer, either by optimizing combinations or by identification of resistance genes.

Dr. William Chi-Shing Cho
is a Scientific Officer at the Department of Clinical Oncology in Queen Elizabeth Hospital. His main research interests focused on cancer studies utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication. He is a Chartered Scientist granted by the Science Council (UK), a Registered Chinese Medicine Practitioner (HK), Guest Professor of many Universities and a Fellow Member of several institutes, including the Institute of Biomedical Science (UK), Hong Kong Institute of Biomedical Science and Hong Kong Society for Molecular Diagnostic Sciences.

Oncology Discovery Subject Areas

Blood Cancer: Leukemia, Lymphoma, Multiple myeloma.
Carcinoma: Breast Cancer, Lung Cancer, Thyroid Cancer.
Genitourinary Cancer: Bladder Cancer, Kidney Cancer, Prostate Cancer, Endometric Cancer.
Gastrointestinal Cancer: Pancreatic Cancer, Colon-rectal Cancer.